Overview Performance Dividends Peer Group Options

(ADMA) ADMA Biologics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0008991046

ADMA: Intravenous Immunoglobulin, Antibody Products, Plasma-Derived Biologics

ADMA Biologics, Inc. specializes in the development, manufacturing, and distribution of plasma-derived biologics, focusing on immune deficiencies and infectious diseases. Its product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments for primary humoral immunodeficiency (PI), and Nabi-HB, a polyclonal antibody for Hepatitis B exposure. The company is expanding its pipeline to address S. pneumoniae infections and operates plasma collection facilities to ensure raw material supply. ADMA distributes its products through a network of wholesalers, pharmacies, and healthcare providers. Headquartered in Ramsey, New Jersey, the company was established in 2004.

Based on and , ADMA is expected to test resistance at 22.0 in the near term, supported by its SMA20 crossover above the SMA50. The ATR of 1.35 suggests moderate volatility. Fundamentally, the high P/B ratio of 14.57 and P/E of 26.31 indicate elevated valuations, which could present a risk if growth slows. The strong RoE of 56.64% supports profitability. Over the next three months, expect price action to remain range-bound between 17.8 and 22.0, with potential upside driven by pipeline advancements and revenue growth. However, caution is warranted near resistance levels due to overvaluation metrics.

Additional Sources for ADMA Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ADMA Stock Overview

Market Cap in USD 5,215m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2013-10-17

ADMA Stock Ratings

Growth Rating 80.0
Fundamental 86.8
Dividend Rating 0.0
Rel. Strength 269
Analysts 4.5/5
Fair Price Momentum 27.56 USD
Fair Price DCF 3.78 USD

ADMA Dividends

No Dividends Paid

ADMA Growth Ratios

Growth Correlation 3m 86.8%
Growth Correlation 12m 67.2%
Growth Correlation 5y 81.8%
CAGR 5y 49.22%
CAGR/Max DD 5y 0.69
Sharpe Ratio 12m 0.72
Alpha 232.90
Beta 1.333
Volatility 63.80%
Current Volume 2782.9k
Average Volume 20d 3173.5k
What is the price of ADMA stocks?
As of May 02, 2025, the stock is trading at USD 23.27 with a total of 2,782,923 shares traded.
Over the past week, the price has changed by +4.21%, over one month by +19.82%, over three months by +41.29% and over the past year by +248.88%.
Is ADMA Biologics a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, ADMA Biologics (NASDAQ:ADMA) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 86.79 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADMA as of May 2025 is 27.56. This means that ADMA is currently undervalued and has a potential upside of +18.44% (Margin of Safety).
Is ADMA a buy, sell or hold?
ADMA Biologics has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy ADMA.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ADMA stock price target?
According to ValueRays Forecast Model, ADMA ADMA Biologics will be worth about 32.3 in May 2026. The stock is currently trading at 23.27. This means that the stock has a potential upside of +38.85%.
Issuer Forecast Upside
Wallstreet Target Price 25.7 10.6%
Analysts Target Price 25.7 10.6%
ValueRay Target Price 32.3 38.8%